Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis.
Fiche publication
Date publication
septembre 2016
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GHIRINGHELLI François, Dr LADOIRE Sylvain, Pr COTTIN Yves, Pr VERGELY Catherine
Tous les auteurs :
Guenancia C, Lefebvre A, Cardinale D, Yu AF, Ladoire S, Ghiringhelli F, Zeller M, Rochette L, Cottin Y, Vergely C
Lien Pubmed
Résumé
Patients with metabolic syndrome have a greater risk of cardiovascular disease, although their susceptibility to chemotherapy-induced cardiac disease is not well documented. The aim of this meta-analysis was to assess associations between obesity or being overweight and cardiotoxicity from anthracyclines and sequential anthracyclines and trastuzumab in patients with breast cancer.
Mots clés
Anthracyclines, adverse effects, Antibiotics, Antineoplastic, adverse effects, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Body Mass Index, Breast Neoplasms, complications, Cardiotoxicity, Female, Heart Diseases, chemically induced, Humans, Obesity, complications, Odds Ratio, Risk Assessment, Risk Factors, Trastuzumab, adverse effects
Référence
J. Clin. Oncol.. 2016 Sep;34(26):3157-65